Kensey Nash Corp <KNSY.O> said it is considering strategic options for its endovascular business and reaffirmed first-quarter earnings and revenue at the high end of its previously announced ...

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics Corporation (Nasdaq:SPNC) today announced it has entered into a definitive agreement to acquire the endovascular business of Kensey Nash ...

Medical device maker Kensey Nash Corp <KNSY.O> agreed to sell its endovascular business to single-use medical device maker Spectranetics Corp <SPNC.O> for $24 million, including possible milestone ...

Philadelphia Business Journal. Select a City Philadelphia Business Journal. 40 Under 40. Meet the 2025 class of ... Kensey Nash first made its mark developing the Angio-Seal, ...

DSM aspires to realize €1 billion ($1.3 billion) in sales by 2020 in its combined emerging business areas, and the company notes that the Kensey Nash acquisition puts it on track to meet this goal.

Kensey Nash Corp.'s board of directors on Tuesday approved a plan by the company's management to cease all activities related to the company's embolic protection devices ... The Business Journals .

Kensey Nash Corporation(Nasdaq: KNSY) announced it has entered into a definitive agreement to sellits endovascular business, including the ThromCat(TM), QuickCat(TM) andSafeCross(TM) ...

“With this acquisition we are putting DSM Biomedical clearly on the map as the second new growth platform for DSM in addition to our biobased products and services business.” Kensey Nash ...